Atrial Fibrillation: JACC Council Perspectives

Simple item page
dc.contributor.authorChung, Mina K.
dc.contributor.authorRefaat, Marwan M.
dc.contributor.authorShen, Win Kuang
dc.contributor.authorKutyifa, Valentina
dc.contributor.authorCha, Yongmei
dc.contributor.authorDi Biase, Luigi
dc.contributor.authorBaranchuk, Adrian
dc.contributor.authorLampert, Rachel J.
dc.contributor.authorNatale, Andrea
dc.contributor.authorFisher, John D.
dc.contributor.authorLakkireddy, Dhanunjaya R.
dc.contributor.departmentInternal Medicine
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:57:23Z
dc.date.available2025-01-24T11:57:23Z
dc.date.issued2020
dc.description.abstractAtrial fibrillation (AF) is an increasingly prevalent arrhythmia; its pathophysiology and progression are well studied. Stroke and bleeding risk models have been created and validated. Decision tools for stroke prophylaxis are evolving, with better options at hand. Utilization of various diagnostic tools offer insight into AF burden and thromboembolic risk. Rate control, rhythm control, and stroke prophylaxis are the cornerstones of AF therapy. Although antiarrhythmic drugs are useful, AF ablation has become a primary therapeutic strategy. Pulmonary vein isolation is the cornerstone of AF ablation, and methods to improve ablation safety and efficacy continue to progress. Ablation of nonpulmonary vein sites is increasingly being recognized as an important strategy for treating nonparoxysmal AF. Several new ablation techniques and technologies and stroke prophylaxis are being explored. This is a contemporary review on the prevalence, pathophysiology, risk prediction, prophylaxis, treatment options, new insights for optimizing treatment outcomes, and emerging concepts of AF. © 2020
dc.identifier.doihttps://doi.org/10.1016/j.jacc.2020.02.025
dc.identifier.eid2-s2.0-85082558264
dc.identifier.pmid32273035
dc.identifier.urihttp://hdl.handle.net/10938/31292
dc.language.isoen
dc.publisherElsevier USA
dc.relation.ispartofJournal of the American College of Cardiology
dc.sourceScopus
dc.subjectAtrial fibrillation
dc.subjectFuture
dc.subjectPresent
dc.subjectAnti-arrhythmia agents
dc.subjectAnticoagulants
dc.subjectCatheter ablation
dc.subjectHumans
dc.subjectRisk assessment
dc.subjectStroke
dc.subjectTreatment outcome
dc.subjectAcetylsalicylic acid
dc.subjectAmiodarone
dc.subjectAndexanet alfa
dc.subjectAngiotensin receptor antagonist
dc.subjectAntiarrhythmic agent
dc.subjectAnticoagulant agent
dc.subjectAntivitamin k
dc.subjectApixaban
dc.subjectAscorbic acid
dc.subjectBeta adrenergic receptor blocking agent
dc.subjectCalcium channel blocking agent
dc.subjectClopidogrel
dc.subjectDigoxin
dc.subjectDipeptidyl carboxypeptidase inhibitor
dc.subjectFibric acid derivative
dc.subjectFresh frozen plasma
dc.subjectHydroxymethylglutaryl coenzyme a reductase inhibitor
dc.subjectIdarucizumab
dc.subjectIrbesartan
dc.subjectMetformin
dc.subjectOctreotide
dc.subjectOmega 3 fatty acid
dc.subjectPlacebo
dc.subjectProthrombin complex
dc.subjectPurinergic p2y receptor antagonist
dc.subjectRivaroxaban
dc.subjectVitamin k group
dc.subjectWarfarin
dc.subjectBleeding
dc.subjectBody weight management
dc.subjectBrain hemorrhage
dc.subjectCardioversion
dc.subjectCerebrovascular accident
dc.subjectCryoablation
dc.subjectDiabetes mellitus
dc.subjectDrug dose titration
dc.subjectDrug withdrawal
dc.subjectDual antiplatelet therapy
dc.subjectEsophagus injury
dc.subjectExercise
dc.subjectFibrosis
dc.subjectGastrointestinal hemorrhage
dc.subjectGene therapy
dc.subjectGenomics
dc.subjectHeart atrium appendage
dc.subjectHeart atrium flutter
dc.subjectHeart atrium remodeling
dc.subjectHospitalization cost
dc.subjectHuman
dc.subjectHyperlipidemia
dc.subjectHypertension
dc.subjectIncidence
dc.subjectInflammation
dc.subjectLifestyle modification
dc.subjectLow drug dose
dc.subjectMetabolic stress
dc.subjectNerve sprouting
dc.subjectNonhuman
dc.subjectOxidative stress
dc.subjectParoxysmal atrial fibrillation
dc.subjectPathophysiology
dc.subjectPersistent atrial fibrillation
dc.subjectPhrenic nerve paralysis
dc.subjectPrediction
dc.subjectPrevalence
dc.subjectPrimary prevention
dc.subjectPriority journal
dc.subjectProtein homeostasis
dc.subjectPulmonary vein isolation
dc.subjectReview
dc.subjectScreening
dc.subjectSecondary prevention
dc.subjectSleep disordered breathing
dc.subjectThromboembolism
dc.subjectVagus nerve injury
dc.subjectComplication
dc.subjectProcedures
dc.titleAtrial Fibrillation: JACC Council Perspectives
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2020-6852.pdf
Size:
2.49 MB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine